Bendamustine in combination with rituximab can be made available within NHS Wales for the treatment of previously untreated and relapsed mantle cell lymphoma in patients currently deemed unsuitable for anthracycline-based therapy or other health technology appraisal-approved regimens.

The risks and benefits of the off-label use of bendamustine plus rituximab for this indication should be clearly stated and discussed with the patient to allow informed consent.

In March 2017 OWMAG recommended this treatment in NHS Wales, in February 2024 there was a review of the recommendation. OWMAG found nothing new that effects the original decision.

Next review: this advice will be reviewed after two years or earlier if new evidence becomes available.